Pharmacokinetic evaluation of proguanil: A probe phenotyping drug for the mephenytoin hydroxylase polymorphism

British Journal of Clinical Pharmacology

Volumn 41, Issue 3, 1996, Pages 175-179

  Somogyi, Andrew A ^a   Reinhard, Helen A ^a   Bochner, Felix ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Cycloguanil; Partial clearance; Pharmacokinetics; Phenotyping; Proguanil

Indexed keywords

CYCLOGUANIL; DRUG METABOLITE; MEPHENYTOIN; PROGUANIL;

ADULT; AEROBIC METABOLISM; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0029877643     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00179.x     Document Type: Article

References (28)

1. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL. A metabolite of 'Paludrine' with high antimalarial activity. Nature 1951; 168: 1080.
2. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990; 30: 593-598.
3. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RE, Breckenridge AM. Intersubject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 1989; 27: 781-787.
4. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br J Clin Pharmacol 1994; 37: 413-420.
5. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306: 240-245.
6. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. Evidence that CYP2C19 is the major (S)-Mephenytoin 4′-hydroxylase in humans. Biochemistry 1993; 33: 1743-1752.
7. Reviriego J, Bertilsson L, Carrillo JA, Llerena A, Valdivielso MJ, Benitez J. Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations. Eur J Clin Pharmacol 1993; 44: 593-595.
8. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
9. Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-397.
10. Sohn D-R, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160-169.
11. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773-780.
12. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-499.
13. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991; 31: 350-352.
14. Jacqz E, Dulac H, Mathieu H. Phenotyping polymorphic drug metabolism in the French Caucasian population. Eur J Clin Pharmacol 1988; 35: 167-171.
15. Abbott JA, Schwab RS. Mesantoin in the treatment of epilepsy: a study of its effect on the leucocyte count in seventy-nine cases. N Engl J Med 1954; 250: 197-199.
16. Setiabudy R, Chiba K, Kusaka M, Ishizaki T. Caution in the use of a 100 mg dose of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992; 33: 665-666.
17. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31: 689-692.
18. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. Clin Pharmacol Ther 1992; 51: 507-512.
19. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993: 36: 105-108.
20. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 1982; 31: 184-186.
21. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986; 22: 541-550.
22. Taylor RB, Moody RR, Ochekpe NA. Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography. J Chromatogr 1987; 416: 394-399.
23. Wattanagoon Y, Taylor RB, Moody RR, Ochekpe NA, Looareesuwan S, White NJ. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 1987; 24: 775-780.
24. Maegraith BG, Tottey MM, Adams ARD, Horner Andrews WH, King JD. The absorption and excretion of paludrine in the human subject. Ann Trop Med Parasitol 1946; 40: 493-506.
25. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4′-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 1995; 39: 297-303.
26. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans Roy Soc Trop Med Hyg 1990; 84: 492-495.
27. Tucker GT, Casey F, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-246.
28. Somogyi A, Keal J, Bochner F. Sensitive high-performance liquid chromatographic assay for determination of amiloride in biologic fluids using an ion-pair extraction method. Ther Drug Monit 1988; 10: 463-468.